Literature DB >> 20033393

[Current strategies of conservative and operative treatment of the most frequent muscular disorders].

A Fujak1, R Forst, J Forst.   

Abstract

Though up to now no causal treatment for the majority of neuromuscular disorders is available, their disease progress and above all the quality of life of these patients can be decisively improved by established medical procedures. The main symptom is variably rapid, progressive muscle weakness, which leads to muscular imbalance and differently manifested impairment of motor functions. This results in the essential orthopaedic problems in these patients, e.g. contractures and deformities of the lower and upper extremities, foot deformities and sitting instability due to progressive scoliosis. Since the affected muscles have no physiological adaptability, they cannot be trained like healthy muscles. The orthopaedic treatment includes conservative methods, e.g. physiotherapy, orthotic devices and aids as well as surgical spine stabilisation and correction of the contractures of the lower extremities. Very important in the care of patients with neuromuscular disorders are the early prophylaxis and treatment of respiratory insufficiency by regular respiratory therapy to learn breathing and coughing techniques and self-exercises as well as the timely initiation of assisted ventilation.

Entities:  

Mesh:

Year:  2010        PMID: 20033393     DOI: 10.1007/s00132-009-1536-1

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  25 in total

1.  The treatment of scoliosis in muscular dystrophy using modified Luque and Harrington-Luque instrumentation.

Authors:  G Bentley; F Haddad; T M Bull; D Seingry
Journal:  J Bone Joint Surg Br       Date:  2001-01

2.  Scoliosis in spinal muscular atrophy: review of 63 cases.

Authors:  E Rodillo; M L Marini; J Z Heckmatt; V Dubowitz
Journal:  J Child Neurol       Date:  1989-04       Impact factor: 1.987

3.  [Segmental spinal instrumentation in neuromuscular scolioses].

Authors:  E R Luque
Journal:  Orthopade       Date:  1989-04       Impact factor: 1.087

4.  Lower limb surgery in Duchenne muscular dystrophy.

Authors:  J Forst; R Forst
Journal:  Neuromuscul Disord       Date:  1999-05       Impact factor: 4.296

5.  Skeletal changes in children with neuromuscular disorders.

Authors:  J D Hsu
Journal:  Prog Clin Biol Res       Date:  1982

6.  Scoliosis and lung function in spinal muscular atrophy.

Authors:  D Robinson; C S Galasko; C Delaney; J B Williamson; J L Barrie
Journal:  Eur Spine J       Date:  1995       Impact factor: 3.134

7.  Spinal muscular atrophy: natural history and orthopaedic treatment of scoliosis.

Authors:  C Granata; L Merlini; E Magni; M L Marini; S B Stagni
Journal:  Spine (Phila Pa 1976)       Date:  1989-07       Impact factor: 3.468

8.  Treatment of scoliosis in intermediate spinal muscular atrophy (SMA type II) in childhood.

Authors:  Albert Fujak; Anne Ingenhorst; Katja Heuser; Raimund Forst; Jürgen Forst
Journal:  Ortop Traumatol Rehabil       Date:  2005-04-30

9.  Importance of lower limb surgery in Duchenne muscular dystrophy.

Authors:  R Forst; J Forst
Journal:  Arch Orthop Trauma Surg       Date:  1995       Impact factor: 3.067

10.  Extremity fractures in children with neuromuscular disease.

Authors:  J D Hsu
Journal:  Johns Hopkins Med J       Date:  1979-09
View more
  3 in total

Review 1.  [Characteristics of neuromuscular scoliosis].

Authors:  M Putzier; C Groß; R K Zahn; M Pumberger; P Strube
Journal:  Orthopade       Date:  2016-06       Impact factor: 1.087

Review 2.  Proximal spinal muscular atrophy: current orthopedic perspective.

Authors:  Gerrit Haaker; Albert Fujak
Journal:  Appl Clin Genet       Date:  2013-11-14

3.  Natural course of scoliosis in proximal spinal muscular atrophy type II and IIIa: descriptive clinical study with retrospective data collection of 126 patients.

Authors:  Albert Fujak; Wolfgang Raab; Alexander Schuh; Silvia Richter; Raimund Forst; Jürgen Forst
Journal:  BMC Musculoskelet Disord       Date:  2013-10-04       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.